{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:29:52Z","timestamp":1790501392687,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"am","delay-in-days":604,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.lpm.2021.104088","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T13:27:30Z","timestamp":1635427650000},"page":"104088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment of systemic sclerosis"],"prefix":"10.1016","volume":"50","author":[{"given":"Benjamin","family":"Thoreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Chaigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2021.104088_bib0001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0002","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.lpm.2021.104088_bib0003","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2021.104062","article-title":"Pulmonary arterial hypertension in systemic sclerosis","volume":"50","author":"Lechartier","year":"2021","journal-title":"Presse Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0005","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lpm.2021.104088_bib0006","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","article-title":"Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)","volume":"76","author":"Herrick","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0007","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0008","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2021.104088_bib0009","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3899\/jrheum.071169","article-title":"Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma","volume":"36","author":"Johnson","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.lpm.2021.104088_bib0011","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0012","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0013","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0014","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/art.30438","article-title":"Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease","volume":"63","author":"Roth","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2021.104088_bib0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00300808","article-title":"Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study","volume":"14","author":"Sharada","year":"1994","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.lpm.2021.104088_bib0016","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2021.104088_bib0017","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2021.104088_bib0018","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2021.104065","article-title":"Autologous stem cell transplantation in scleroderma","volume":"50","author":"Farge","year":"2021","journal-title":"Presse Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0020","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/rheumatology\/kex410","article-title":"Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study","volume":"57","author":"Peytrignet","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2021.104088_bib0021","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/acr.23098","article-title":"Personalized physical therapy versus usual care for patients with systemic sclerosis: a randomized controlled trial","volume":"69","author":"Rannou","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.lpm.2021.104088_bib0022","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0023","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0024","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"Suppl 125","key":"10.1016\/j.lpm.2021.104088_bib0025","first-page":"161","article-title":"Intravenous versus oral cyclophosphamide for lung and\/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials","volume":"38","author":"Bruni","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0026","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0027","first-page":"1064","article-title":"Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study","volume":"35","author":"B\u00e9rezn\u00e9","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0028","first-page":"234","article-title":"Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease","volume":"1","author":"Launay","year":"2016","journal-title":"J Sclerod Rel Disord"},{"key":"10.1016\/j.lpm.2021.104088_bib0029","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0030","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0031","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/rheumatology\/ker271","article-title":"Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls","volume":"51","author":"Guillevin","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.lpm.2021.104088_bib0032","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.lpm.2021.104088_bib0033","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.lpm.2021.104088_bib0034","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.lpm.2021.104088_bib0035","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0036","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"Suppl 113","key":"10.1016\/j.lpm.2021.104088_bib0037","first-page":"142","article-title":"Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study","volume":"36","author":"Fraticelli","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0038","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2021.104088_bib0039","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0040","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0041","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.41576","article-title":"Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of a randomized, double-blind, placebo-controlled trial","volume":"73","author":"Maher","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0042","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0043","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1513\/AnnalsATS.201503-177OC","article-title":"Lung transplant in patients with scleroderma compared with pulmonary fibrosis. short- and long-term outcomes","volume":"13","author":"Crespo","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.lpm.2021.104088_bib0044","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.semarthrit.2016.02.004","article-title":"Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study","volume":"46","author":"Richardson","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.lpm.2021.104088_bib0045","article-title":"Calcium channel blockers for primary and secondary Raynaud's phenomenon","volume":"12","author":"Rirash","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lpm.2021.104088_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.01.043","article-title":"A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud's phenomenon","volume":"78","author":"Curtiss","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2021.104064","article-title":"Digital ulcers in systemic sclerosis","volume":"50","author":"Hughes","year":"2021","journal-title":"Presse Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0048","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bmj.298.6673.561","article-title":"Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study","volume":"298","author":"Rademaker","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2021.104088_bib0049","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10238-019-00553-y","article-title":"Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study","volume":"19","author":"Negrini","year":"2019","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0050","first-page":"1407","article-title":"Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis","volume":"19","author":"Wigley","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0051","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0052","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acr.22018","article-title":"Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis","volume":"65","author":"Tingey","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.lpm.2021.104088_bib0053","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/jcph.1574","article-title":"Treprostinil hydrogel iontophoresis in systemic sclerosis-related digital skin ulcers: a safety study","volume":"60","author":"Guigui","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.lpm.2021.104088_bib0054","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2021.104088_bib0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0056","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/jama.2016.5258","article-title":"Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials","volume":"315","author":"Khanna","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2021.104088_bib0057","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2014.04.028","article-title":"Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study","volume":"71","author":"Chung","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0058","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","article-title":"Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study","volume":"75","author":"Hachulla","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0059","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.lpm.2021.104088_bib0060","first-page":"1801","article-title":"Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers","volume":"35","author":"Abou-Raya","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0061","first-page":"499","article-title":"Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study","volume":"18","author":"Denton","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0062","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2340\/00015555-2665","article-title":"Efficacy of botulinum Toxin B Injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis","volume":"97","author":"Motegi","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.lpm.2021.104088_bib0063","first-page":"642","article-title":"Surgery of the hand in patients with systemic sclerosis: outcomes and considerations","volume":"32","author":"Bogoch","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0064","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0065","first-page":"21","article-title":"Mortality and morbidity in scleroderma renal crisis: a systematic literature review","volume":"6","author":"Kim","year":"2021","journal-title":"J Sclerod Rel Disord"},{"key":"10.1016\/j.lpm.2021.104088_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2021.104063","article-title":"Scleroderma renal crisis","volume":"50","author":"Hudson","year":"2021","journal-title":"Presse Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0067","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.40809","article-title":"Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology","volume":"71","author":"Butler","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0068","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0069","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-133-8-200010170-00010","article-title":"Long-term outcomes of scleroderma renal crisis","volume":"133","author":"Steen","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0070","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.semarthrit.2013.09.008","article-title":"International Scleroderma Renal Crisis Study Investigators. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey","volume":"43","author":"Hudson","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.lpm.2021.104088_bib0071","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s13023-021-01844-y","article-title":"French recommendations for the management of systemic sclerosis","volume":"16","author":"Hachulla","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0072","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","article-title":"Scleroderma renal crisis: patient characteristics and long-term outcomes","volume":"100","author":"Penn","year":"2007","journal-title":"QJM"},{"key":"10.1016\/j.lpm.2021.104088_bib0073","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101668","article-title":"Cardiac involvement in systemic sclerosis: getting to the heart of the matter","volume":"35","author":"Bruni","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.rdc.2013.10.007","article-title":"Systemic sclerosis and the heart","volume":"40","author":"Parks","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.lpm.2021.104088_bib0076","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrgastro.2016.99","article-title":"Current management of the gastrointestinal complications of systemic sclerosis","volume":"13","author":"Emmanuel","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0077","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2036.1992.tb00571.x","article-title":"Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis","volume":"6","author":"Hendel","year":"1992","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.lpm.2021.104088_bib0078","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2036.1993.tb00126.x","article-title":"The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: the effect of low-dose omeprazole","volume":"7","author":"Shoenut","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.lpm.2021.104088_bib0079","first-page":"15","article-title":"Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole","volume":"27","author":"Muro","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0080","first-page":"5","article-title":"Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?","volume":"27","author":"Pakozdi","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0081","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/rheumatology\/kew216","article-title":"Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial","volume":"56","author":"Foocharoen","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.lpm.2021.104088_bib0082","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0016-5085(87)91020-1","article-title":"Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis","volume":"93","author":"Horowitz","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2021.104088_bib0083","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/apt.12479","article-title":"Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth","volume":"38","author":"Shah","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.lpm.2021.104088_bib0084","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MCG.0000000000000814","article-title":"Probiotics for preventing and treating small intestinal bacterial overgrowth: a meta-analysis and systematic review of current evidence","volume":"51","author":"Zhong","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.lpm.2021.104088_bib0085","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/rheumatology\/key175","article-title":"Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review","volume":"57","author":"Pittman","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.lpm.2021.104088_bib0086","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s10620-019-05830-0","article-title":"Effectiveness of saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis","volume":"65","author":"Garc\u00eda-Collinot","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.lpm.2021.104088_bib0087","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1007\/BF02208652","article-title":"Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction","volume":"40","author":"Verne","year":"1995","journal-title":"Digest Dis Sci"},{"key":"10.1016\/j.lpm.2021.104088_bib0088","first-page":"119","article-title":"Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients","volume":"13","author":"Nikou","year":"2007","journal-title":"JCR"},{"key":"10.1016\/j.lpm.2021.104088_bib0089","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13075-017-1340-y","article-title":"Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study","volume":"19","author":"Vigone","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2021.104088_bib0090","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/nmo.12735","article-title":"Comparative quantitative assessment of global small bowel motility using magnetic resonance imaging in chronic intestinal pseudo-obstruction and healthy controls","volume":"28","author":"Menys","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.lpm.2021.104088_bib0091","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MCG.0000000000001047","article-title":"Pathophysiology, diagnosis, and management of chronic intestinal pseudo-obstruction","volume":"52","author":"Downes","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.lpm.2021.104088_bib0092","first-page":"S42","article-title":"Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel","volume":"28","author":"Baron","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0093","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/0148607115597883","article-title":"Medical nutrition therapy for patients with advanced systemic sclerosis (MNT PASS): a pilot intervention study","volume":"41","author":"Doerfler","year":"2017","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.lpm.2021.104088_bib0094","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/rheumatology\/kem329","article-title":"Home parenteral nutrition\u2013an effective and safe long-term therapy for systemic sclerosis-related intestinal failure","volume":"47","author":"Brown","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2021.104088_bib0095","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.rdc.2015.04.011","article-title":"Musculoskeletal manifestations of systemic sclerosis","volume":"41","author":"Morrisroe","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.lpm.2021.104088_bib0096","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/acr.20320","article-title":"Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study","volume":"62","author":"Au","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.lpm.2021.104088_bib0097","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0098","first-page":"1636","article-title":"Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease","volume":"34","author":"Lam","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0099","first-page":"S55","article-title":"Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis","volume":"30","author":"Omair","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0100","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1136\/ard.2008.096123","article-title":"An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis","volume":"68","author":"Denton","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0101","first-page":"S40","article-title":"Is there a role for TNF\u03b1 antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique","volume":"29","author":"Distler","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0102","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0103","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.lpm.2021.104088_bib0104","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0105","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/ard.2008.095919","article-title":"A descriptive and prognostic study of systemic sclerosis-associated myopathies","volume":"68","author":"Ranque","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0106","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/03009741003774626","article-title":"Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features","volume":"39","author":"Ranque","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102431","article-title":"Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: a comparative study in 52 patients","volume":"19","author":"Chaigne","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"Suppl 100","key":"10.1016\/j.lpm.2021.104088_bib0108","first-page":"157","article-title":"Occupational therapy integrated with a self-administered stretching program on systemic sclerosis patients with hand involvement","volume":"34","author":"Stefanantoni","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0109","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00296-010-1382-9","article-title":"The rehabilitation of facial involvement in systemic sclerosis: efficacy of the combination of connective tissue massage, Kabat's technique and kinesitherapy: a randomized controlled trial","volume":"31","author":"Maddali-Bongi","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.lpm.2021.104088_bib0110","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/art.30071","article-title":"Cigarette smoking in patients with systemic sclerosis","volume":"63","author":"Hudson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2021.104088_bib0111","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/art.10685","article-title":"Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis","volume":"46","author":"Harrison","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2021.104088_bib0112","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3899\/jrheum.131210","article-title":"Scleroderma renal crisis","volume":"41","author":"Mouthon","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0113","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jviscsurg.2010.06.001","article-title":"Erythromycin as a prokinetic agent: risk factors","volume":"147","author":"Berthet","year":"2010","journal-title":"J Visc Surg"},{"key":"10.1016\/j.lpm.2021.104088_bib0114","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.113.004526","article-title":"Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)","volume":"129","author":"Olsson","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2021.104088_bib0115","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.115.018435","article-title":"Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH Disease Management (REVEAL)","volume":"132","author":"Preston","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2021.104088_bib0116","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13073-020-00779-6","article-title":"Epigenomics and transcriptomics of systemic sclerosis CD4+ T cells reveal long-range dysregulation of key inflammatory pathways mediated by disease-associated susceptibility loci","volume":"12","author":"Li","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.lpm.2021.104088_bib0117","article-title":"Systematic approach to understanding the pathogenesis of systemic sclerosis","author":"Zuo","year":"2016","journal-title":"Clin Genet"},{"key":"10.1016\/j.lpm.2021.104088_bib0118","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","article-title":"Nilotinib (Tasigna\u2122) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial","volume":"17","author":"Gordon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2021.104088_bib0119","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3899\/jrheum.160833","article-title":"Proteomic analysis of sera from individuals with diffuse cutaneous systemic sclerosis reveals a multianalyte signature associated with clinical improvement during imatinib mesylate treatment","volume":"44","author":"Haddon","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0120","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-015-0669-3","article-title":"Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis","volume":"17","author":"Chakravarty","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2021.104088_bib0121","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-021-02536-5","article-title":"An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3\u2009years","volume":"23","author":"Campochiaro","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2021.104088_bib0122","doi-asserted-by":"crossref","first-page":"12319","DOI":"10.1073\/pnas.1635114100","article-title":"Systemic and cell type-specific gene expression patterns in scleroderma skin","volume":"100","author":"Whitfield","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.lpm.2021.104088_bib0123","doi-asserted-by":"crossref","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"Milano","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.lpm.2021.104088_bib0124","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1002\/art.39289","article-title":"Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis","volume":"67","author":"Assassi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0125","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/jid.2013.130","article-title":"Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis","volume":"133","author":"Hinchcliff","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0126","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","article-title":"Association of Interferon- and transforming growth factor \u03b2-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis","volume":"66","author":"Christmann","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0127","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/art.30159","article-title":"Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension","volume":"63","author":"Hsu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2021.104088_bib0128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","article-title":"Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2021.104088_bib0129","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/acr2.11049","article-title":"Safety and tolerability of thrombin inhibition in scleroderma-associated interstitial lung disease","volume":"1","author":"Silver","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0130","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/art.30549","article-title":"Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center","volume":"63","author":"Pope","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2021.104088_bib0131","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase ii investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 113","key":"10.1016\/j.lpm.2021.104088_bib0132","first-page":"146","article-title":"Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I\/II biomarker trial","volume":"36","author":"Mantero","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0133","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2021.104088_bib0134","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, Phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2021.104088_bib0135","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.lpm.2021.104088_bib0136","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-018-1792-8","article-title":"Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study","volume":"21","author":"Del Papa","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2021.104088_bib0137","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.humpath.2010.05.018","article-title":"Endothelin-1 expression in scleroderma renal crisis","volume":"42","author":"Mouthon","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.lpm.2021.104088_bib0138","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/qjmed\/hct111","article-title":"Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility","volume":"106","author":"Penn","year":"2013","journal-title":"QJM"},{"key":"10.1016\/j.lpm.2021.104088_bib0139","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/2397198319885488","article-title":"Mammalian target of rapamycin is activated in the kidneys of patients with scleroderma renal crisis","volume":"5","author":"Salituri","year":"2020","journal-title":"Journal of Scleroderma and Related Disorders"},{"key":"10.1016\/j.lpm.2021.104088_bib0140","doi-asserted-by":"crossref","first-page":"e4459","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.lpm.2021.104088_bib0141","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232739","article-title":"Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial","volume":"15","author":"Fretheim","year":"2020","journal-title":"PLoS ONE"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498221000270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498221000270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:07:41Z","timestamp":1760105261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498221000270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":141,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0755498221000270"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2021.104088","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2021.104088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104088"}}